Importantly, in contrast to infection experiments using highly pathogenic SARS-CoV-2, the DSP assay can be performed under biosafety level 1 (BSL-1) containment to characterize spike protein fusion activity and to screen for antibodies or compounds that inhibit the fusion process (Chen and Reuter et al., unpublished). This evidence concerns the gene CHMP5 and infection.